Loss of PTEN (phosphatase and tensin homolog), a major negative regulator of the PI3K/AKT signaling is significantly associated with advanced disease, chemotherapy resistance, and poor survival in DLBCL patients with DLBCL with AKT hyperactivation11–13. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.